Copley Acquisition Corp
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $248.9M
- Price
- $10.49
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.10%
- Volume
- 2.2K
About
Copley Acquisition Corp currently does not engage in significant business activities. This entity's primary objective is to execute a strategic business combination, such as a merger, acquisition, or reorganization, with one or more operating companies. It plans to concentrate its search for suitable partners within the technology and lifestyle industries across the Asia Pacific and North American regions. Established in 2024, the company's principal office is situated in Central, Hong Kong.
Quick stats
Shares outstanding23.7M
Computed float17.4M
Float / shares73.4%
Key info
SectorFinancial Services
IndustryShell Companies
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002045473
AI Summary
AI-generated1/2
criticalbullishm and a
Copley Acquisition Corp (NYSE: COPL) and Ignite Proteomics Announce Business Combination Agreement to Advance Precision Oncology
Copley Acquisition Corp has entered into a definitive business combination agreement with Ignite Proteomics, a pioneer in pathway-level protein analytics for precision oncology.
The transaction values Ignite at a $150 million pro forma enterprise value and will result in the formation of a new public holding company, Ignite Proteomics Holdings, Inc., listed on the NYSE.
Closing is expected in the second half of 2026, subject to customary conditions including shareholder approval. The deal marks the transition of Ignite from a private entity to a publicly traded company focused on breast cancer and broader oncology applications.
Red flags
- SPAC merger carries execution risk; closing is subject to shareholder vote and customary conditions
- Target is pre-revenue/pre-commercial; valuation relies on future technology adoption and clinical validation